Literature DB >> 17392286

Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells.

Wei Jin1, William R Reiley, Andrew J Lee, Ato Wright, Xuefeng Wu, Minying Zhang, Shao-Cong Sun.   

Abstract

Deubiquitinating enzymes (DUB) form a family of cysteine proteases that digests ubiquitin chains and reverses the process of protein ubiquitination. Despite the identification of a large number of DUBs, their physiological functions remain poorly defined. Here we provide genetic evidence that CYLD, a recently identified DUB, plays a crucial role in regulating the peripheral development and activation of B cells. Disruption of the CYLD gene in mice results in B cell hyperplasia and lymphoid organ enlargement. The CYLD-deficient B cells display surface markers indicative of spontaneous activation and are hyperproliferative upon in vitro stimulation. When challenged with antigens, the CYLD(-/-) mice develop exacerbated lymphoid organ abnormalities and abnormal B cell responses. Although the loss of CYLD has only a minor effect on B cell development in bone marrow, this genetic deficiency disrupts the balance of peripheral B cell populations with a significant increase in marginal zone B cells. In keeping with these functional abnormalities, the CYLD(-/-) B cells exhibit constitutive activation of the transcription factor NF-kappaB due to spontaneous activation of IkappaB kinase beta and degradation of the NF-kappaB inhibitor IkappaBalpha. These findings demonstrate a critical role for CYLD in regulating the basal activity of NF-kappaB and maintaining the naive phenotype and proper activation of B cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392286     DOI: 10.1074/jbc.M609952200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Roles of the NF-kappaB pathway in lymphocyte development and function.

Authors:  Steve Gerondakis; Ulrich Siebenlist
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

Review 2.  Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections.

Authors:  Wenzhuo Y Wang; Jae Hyang Lim; Jian-Dong Li
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

Review 3.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 4.  CYLD-mediated signaling and diseases.

Authors:  Bryan J Mathis; Yimu Lai; Chen Qu; Joseph S Janicki; Taixing Cui
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 5.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

Review 6.  Regulation of NF-κB by deubiquitinases.

Authors:  Edward W Harhaj; Vishva M Dixit
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 7.  Emerging role of ubiquitination in antiviral RIG-I signaling.

Authors:  Jonathan Maelfait; Rudi Beyaert
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

Review 8.  CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different.

Authors:  Marie Lork; Kelly Verhelst; Rudi Beyaert
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

9.  Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.

Authors:  Wei Jin; Mikyoung Chang; Emmanuel M Paul; Geetha Babu; Andrew J Lee; William Reiley; Ato Wright; Minying Zhang; Jun You; Shao-Cong Sun
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  A new look at T cell receptor signaling to nuclear factor-κB.

Authors:  Suman Paul; Brian C Schaefer
Journal:  Trends Immunol       Date:  2013-03-07       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.